搜索拜瑞妥－疗效卓越、安全可靠、使用简便
拜瑞妥－直接抑制Xa因子
拜瑞妥是首个进入临床使用的直接Xa因子抑制剂。它是新一代Xa因子抑制剂的引导者，以满足日益迫切的对改善的抗栓治疗的需求。在中国，已获准用于成年择期髋关节或膝关节置换术患者VTE的预防。1
在RECORD1, 3和4中，拜瑞妥预防择期髋关节或膝关节置换术患者VTE的疗效显著优于依诺肝素，而安全性与依诺肝素相当。2, 4, 9
在RECORD2研究中，比较了拜瑞妥5周治疗与依诺肝素2周治疗，同样，拜瑞妥的疗效显著优于依诺肝素，而安全性与依诺肝素相当。3
在RECORD2研究中，比较了拜瑞妥5周治疗与依诺肝素2周治疗，同样，拜瑞妥的疗效显著优于依诺肝素，而安全性与依诺肝素相当。3
其他治疗方法
磺达肝癸钠是一种间接Xa因子抑制剂，皮下注射给药。8 但是它不能抑制凝血酶原结合的Xa因子，对血凝块结合的Xa因子也无效。
华法林可通过口服给药，其治疗窗狭窄，需要对抗凝效果进行严格的监测。另外其抗凝效果可因为与食物或其他药物的相互作用而受到明显的影响。因此华法林治疗不达标的风险非常大30 ，可能会导致非常严重的后果，比如大出血或血栓形成等。
- 1 - 拜瑞妥产品说明书
- 29 - Lohrmann J, Becker RC. New anticoagulants—the path from discovery to clinical practice. N Engl J Med. 2008;358(26):2827-2829.
- 2 - Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
- 4 - Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
- 9 - International Congress on Thrombosis: Rivaroxaban is first novel oral anticoagulant to significantly reduce the composite outcome of symptomatic VTE and death [press release]. Leverkusen, Germany: Bayer HealthCare AG; June 30, 2008.
- 3 - Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39.
- 7 - Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.
- 27 - Haas S. New oral Xa and IIa inhibitors: updates on clinical trial results. J Thromb Thrombolysis. 2008;25(1):52-60.
- 8 - Kubitza D, Haas S. Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opin Investig Drugs. 2006;15(8):843-855.
- 30 - Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):160S-198S.
